Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-11-14 4:33 pm Purchase | 13G | ARRIVENT BIOPHARMA INC AVBP | HHLR ADVISORS LTD. | 4,484,672 13.400% | 4,484,672 (New Position) | View |
2024-11-12 2:45 pm Purchase | 13G | ARRIVENT BIOPHARMA INC AVBP | Sofinnova Venture Partners XI L.P. | 1,696,752 5.100% | 1,696,752 (New Position) | View |
2024-11-12 09:50 am Purchase | 13G | ARRIVENT BIOPHARMA INC AVBP | FMR LLC | 2,119,695 6.311% | 2,119,695 (New Position) | View |
2024-11-08 2:17 pm Unchanged | 13G | ARRIVENT BIOPHARMA INC AVBP | BlackRock Inc. | 1,931,419 5.800% | 0 (Unchanged) | View |
2024-10-24 2:02 pm Purchase | 13G | ARRIVENT BIOPHARMA INC AVBP | BlackRock Inc. | 1,931,419 5.800% | 1,931,419 (New Position) | View |
2024-10-11 4:02 pm Purchase | 13G | ARRIVENT BIOPHARMA INC AVBP | Octagon Capital Advisors LP | 1,976,387 5.900% | 1,976,387 (New Position) | View |
2024-02-13 5:20 pm Purchase | 13G | ARRIVENT BIOPHARMA INC AVBP | LAV Fund VI L.P. | 2,046,123 6.400% | 2,046,123 (New Position) | View |
2024-02-05 4:42 pm Purchase | 13D | ARRIVENT BIOPHARMA INC AVBP | ORBIMED ADVISORS LLC | 3,027,328 9.100% | 3,027,328 (New Position) | View |